论文部分内容阅读
近年来,越来越多的尿毒症患者接受了肾移植手术,环孢素(cycolsporine,CsA)为同种异体移植的首选药物,但该药的生物利用度较低,个体差异大,易受生理、病理、食物及合并用药等诸多因素影响。据资料表明:服用CsA引起肾毒性发生率为50%-70%,环孢素致肝损害的发生率为10%-50%。我院自2000年1月-2003年7月对肾移植术后服用CsA的患者进行了药学监护,收到了一定效果。
In recent years, more and more uremic patients underwent renal transplantation. Cyclosporine (CsA) is the drug of choice for allogeneic transplantation. However, the drug has low bioavailability, high individual variability, Physiology, pathology, food and medication and many other factors. According to the data, the incidence of renal toxicity caused by CsA was 50% -70%, and the incidence of hepatic damage caused by cyclosporine was 10% -50%. In our hospital from January 2000 to July 2003 after renal transplantation patients taking CsA for medical care, received some results.